193 related articles for article (PubMed ID: 38516238)
1. Evaluating the influence of sarcopenia and myosteatosis on clinical outcomes in gastric cancer patients undergoing immune checkpoint inhibitor.
Deng GM; Song HB; Du ZZ; Xue YW; Song HJ; Li YZ
World J Gastroenterol; 2024 Feb; 30(8):863-880. PubMed ID: 38516238
[TBL] [Abstract][Full Text] [Related]
2. Progressive sarcopenia and myosteatosis predict prognosis of advanced HCC patients treated with immune checkpoint inhibitors.
Liu M; Jin Q; Wang H; Li Y
Front Immunol; 2024; 15():1396927. PubMed ID: 38690276
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors.
Kim YY; Lee J; Jeong WK; Kim ST; Kim JH; Hong JY; Kang WK; Kim KM; Sohn I; Choi D
Gastric Cancer; 2021 Mar; 24(2):457-466. PubMed ID: 32970267
[TBL] [Abstract][Full Text] [Related]
4. Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma.
Chen BB; Liang PC; Shih TT; Liu TH; Shen YC; Lu LC; Lin ZZ; Hsu C; Hsu CH; Cheng AL; Shao YY
Eur Radiol; 2023 Jan; 33(1):512-522. PubMed ID: 35864351
[TBL] [Abstract][Full Text] [Related]
5. Nutritional status and skeletal muscle status in patients with head and neck cancer: Impact on outcomes.
Findlay M; White K; Brown C; Bauer JD
J Cachexia Sarcopenia Muscle; 2021 Dec; 12(6):2187-2198. PubMed ID: 34676673
[TBL] [Abstract][Full Text] [Related]
6. Deep learning-based assessment of CT markers of sarcopenia and myosteatosis for outcome assessment in patients with advanced pancreatic cancer after high-intensity focused ultrasound treatment.
Nowak S; Kloth C; Theis M; Marinova M; Attenberger UI; Sprinkart AM; Luetkens JA
Eur Radiol; 2024 Jan; 34(1):279-286. PubMed ID: 37572195
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Artificial Intelligence-Driven, Computed Tomography-Based, Volumetric Assessment of the Volume and Density of Muscle in Patients With Colon Cancer.
Kim M; Lee SM; Son IT; Park T; Oh BY
Korean J Radiol; 2023 Sep; 24(9):849-859. PubMed ID: 37634640
[TBL] [Abstract][Full Text] [Related]
8. Different computed tomography parameters for defining myosteatosis in patients with advanced non-small cell lung cancer.
Zhang W; Tang J; Tang H; Xie L; Wang J; Wu J; Yang M
Clin Nutr; 2023 Dec; 42(12):2414-2421. PubMed ID: 37871482
[TBL] [Abstract][Full Text] [Related]
9. Sarcopenia and myosteatosis in patients undergoing curative radiotherapy for head and neck cancer: Impact on survival, treatment completion, hospital admission and cost.
Findlay M; Brown C; De Abreu Lourenço R; White K; Bauer J
J Hum Nutr Diet; 2020 Dec; 33(6):811-821. PubMed ID: 32609428
[TBL] [Abstract][Full Text] [Related]
10. Computed tomography (CT)-defined sarcopenia and myosteatosis are prevalent in patients with neuroendocrine neoplasms (NENs) treated with peptide receptor radionuclide therapy (PRRT).
Chan DL; Clarke SJ; Engel A; Diakos CI; Pavlakis N; Roach PJ; Bailey DL; Bauer J; Findlay M
Eur J Clin Nutr; 2022 Jan; 76(1):143-149. PubMed ID: 33986486
[TBL] [Abstract][Full Text] [Related]
11. Impact of preoperative sarcopenia and myosteatosis on prognosis after radical cystectomy in patients with bladder cancer.
Yamashita S; Iguchi T; Koike H; Wakamiya T; Kikkawa K; Kohjimoto Y; Hara I
Int J Urol; 2021 Jul; 28(7):757-762. PubMed ID: 33821510
[TBL] [Abstract][Full Text] [Related]
12. Skeletal muscle alterations indicate poor prognosis in cirrhotic patients: a multicenter cohort study in China.
Zeng X; Shi ZW; Yu JJ; Wang LF; Sun CY; Luo YY; Shi PM; Lin Y; Chen YX; Guo J; Zhang CQ; Xie WF
Hepatol Int; 2024 Apr; 18(2):673-687. PubMed ID: 37332023
[TBL] [Abstract][Full Text] [Related]
13. Obesity is Associated with Longer Survival Independent of Sarcopenia and Myosteatosis in Metastatic and/or Castrate-Resistant Prostate Cancer.
Xu MC; Huelster HL; Hatcher JB; Avulova S; Stocks BT; Glaser ZA; Moses KA; Silver HJ
J Urol; 2021 Mar; 205(3):800-805. PubMed ID: 33080148
[TBL] [Abstract][Full Text] [Related]
14. Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors.
Martini DJ; Shabto JM; Goyal S; Liu Y; Olsen TA; Evans ST; Magod BL; Ravindranathan D; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Joshi SS; Kissick HT; Ogan KE; Harris WB; Kucuk O; Carthon BC; Master VA; Bilen MA
Oncologist; 2021 Dec; 26(12):1017-1025. PubMed ID: 34342095
[TBL] [Abstract][Full Text] [Related]
15. Effects of Sarcopenia, Myosteatosis, and the Prognostic Nutritional Index on Survival in Stage 2 and 3 Gastric Cancer Patients.
Bir Yucel K; Karabork Kilic AC; Sutcuoglu O; Yazıcı O; Aydos U; Kilic K; Özdemir N
Nutr Cancer; 2023; 75(1):368-375. PubMed ID: 36093734
[TBL] [Abstract][Full Text] [Related]
16. Myosteatosis predicts prognosis after radical gastrectomy for gastric cancer: A propensity score-matched analysis from a large-scale cohort.
Zhuang CL; Shen X; Huang YY; Zhang FM; Chen XY; Ma LL; Chen XL; Yu Z; Wang SL
Surgery; 2019 Sep; 166(3):297-304. PubMed ID: 31072665
[TBL] [Abstract][Full Text] [Related]
17. Body composition change indices combined with Prognostic Nutritional Index predicts the clinical outcomes of patients with gastric cancer treated with immune checkpoint inhibitor.
Deng G; Zhu D; Du Z; Xue Y; Song H; Li Y
Cancer Med; 2024 Mar; 13(6):e7110. PubMed ID: 38506237
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Sarcopenia and Myosteatosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma.
Kim DW; Ahn H; Kim KW; Lee SS; Kim HJ; Ko Y; Park T; Lee J
Korean J Radiol; 2022 Nov; 23(11):1055-1066. PubMed ID: 36098341
[TBL] [Abstract][Full Text] [Related]
19. Varying clinical relevance of sarcopenia and myosteatosis according to age among patients with postoperative colorectal cancer.
Cho HJ; Lee HS; Kang J
J Nutr Health Aging; 2024 Apr; 28(7):100243. PubMed ID: 38643603
[TBL] [Abstract][Full Text] [Related]
20. The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma.
Rollins KE; Tewari N; Ackner A; Awwad A; Madhusudan S; Macdonald IA; Fearon KC; Lobo DN
Clin Nutr; 2016 Oct; 35(5):1103-9. PubMed ID: 26411749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
